Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 448Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Breast Neoplasms 161Triple Negative Breast Neoplasms 160Neoplasm Metastasis 155Lung Neoplasms 140Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 72Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Glioblastoma 39Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Lymphoma 34

Interventions

Gemcitabine 4lenvatinib 3durvalumab 3Cisplatin 3tislelizumab 2sintilimab 2pembrolizumab 2toripalimab 1titanium silicide 1theasinensin A 1surufatinib 1sitravatinib 1regorafenib 1S 1 (combination) 1Nivolumab 1Injections 1Folfox protocol 1Fluorouracil 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Biliary Tract Cancer × pembrolizumab × Clear all
NCT06978114 2025-07-02

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT06708858 2024-11-27

Phase â…¡ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡